From Nasdaq: 2025-05-31 09:36:00

Genentech, a member of the Roche Group, reported positive final results from the Phase III INAVO120 study. The data showed that Itovebi, in combination with palbociclib and fulvestrant, reduced the risk of death by over 30% in people with PIK3CA-mutated, HR-positive, HER2-negative, endocrine-resistant breast cancer. The Itovebi-based regimen also demonstrated a significant improvement in overall survival, with a median of 34.0 months compared to 27.0 months in the comparator arm. Additionally, the regimen showed consistent improvement in progression free survival and delayed time to chemotherapy. No new safety concerns were observed.



Read more at Nasdaq: Phase III Study Shows Genentech’s Itovebi Combo Cuts Death Risk By 30% In Advanced Breast Cancer